NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cartesian Therapeutics, Inc. RNAC
12 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 400,000.00
Revenue, FY2025 · full 12-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.4 · Net income -130.3
Compound annual growth
Revenue compounded at −52.5% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−32576 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -35851.2% · Net -32575.5%
ROE
FY2022 · ROE 60.8%
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.0 | −0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.0 | −0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · |
| Net income $B | −0.1 | −0.1 | −0.2 | 0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | −0.1 | −0.0 | −0.1 | 0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −5.02 | −4.49 | −49.76 | 0.10 | −0.22 | −0.68 | −1.22 | −2.92 | −3.20 | −3.89 | −15.13 | −7.84 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | 60.8 | −1137.9 | · | −3716.0 | −281.6 | −122.4 | · | · | · |
| Shares out B | 0.03 | 0.03 | 0.01 | 0.15 | 0.12 | 0.11 | 0.09 | 0.02 | · | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 44 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 32 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014